5 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 10 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
Follow GnRH antagonist: new trials by email Literature Review of GnRH antagonist trials Research Report on GnRH antagonist
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Not yet recruiting | ShangHai Ji Ai Genetics & IVF Institute | 204 | 2027-06-01 | 2026-11-09 |
| Effect of GH on the Blastocyst Euploid Rate in AMA Patients Growth Hormone, GnRH antagonist - Preimplantation Genetic Testing, Growth Hormone | Phase 3 | Recruiting | ShangHai Ji Ai Genetics & IVF Institute | 400 | 2022-08-01 | 2025-02-12 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients GnRH antagonist, Letrozole 2.5mg - Endometrial Neoplasms, Atypical Endometrial Hyperplasia | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2026-09-10 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients GnRH antagonist, Letrozole 2.5mg - Atypical Endometrial Hyperplasia, Progesterone Resistance | Phase 2 / Phase 3 | Active not recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2025-08-11 |
| Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study Growth hormone, GnRH antagonist - Growth Hormone, Advanced Maternal Age | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 692 | 2021-01-01 | 2023-02-21 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A GnRH antagonist, oral Duphaston - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 400 | 2020-06-10 | 2025-05-31 |
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Progesterone, GnRH Antagonist - IVF, GnRH Antagonist | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 784 | 2020-06-04 | 2023-08-30 |
| PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate placebo acyline, placebo gel, Testosterone 1% gel 1.25 g - Healthy | Phase 2 / Phase 3 | Completed | University of Washington | 62 | 2011-10-01 | 2017-10-05 |
| Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) Corifollitropin alfa, FSH, GnRH antagonist - In Vitro Fertilization | Phase 3 | Completed | Organon and Co | 682 | 2006-09-26 | 2024-06-18 |
| The Effects of Aging and Estrogen on the Pituitary GnRH, NAL-GLU GnRH antagonist, Estrogen patch - Healthy | Phase 2 / Phase 3 | Unknown | Massachusetts General Hospital | 19 | 2002-01-01 | 2017-04-13 |
Endometrial Hyperplasia (2) · Obesity (2) · Progesterone Resistance (2) · Endometrial Neoplasms (1) · Infertility (1) · Polycystic Ovary Syndrome (1)
ShangHai Ji Ai Genetics & IVF Institute (5) · Xiaojun Chen (2) · Massachusetts General Hospital (1) · Organon and Co (1) · University of Washington (1)
China (6) · United States (2)
Janet E Hall, M.D. (1) · Stephanie T Page, MD, PhD (1) · Xiaoxi Sun, PhD (1)
PMID 19549740, PMID 20133465, PMID 21622693, PMID 26187300, PMID 26950065, PMID 26991902, PMID 27172434, PMID 37858247, PMID 38272383, PMID 38521533, PMID 41735936, PMID 42819751
2004 (1), R01AG013241 (1), R01AG037603 (1)